25 min listen
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
ratings:
Length:
26 minutes
Released:
Aug 29, 2023
Format:
Podcast episode
Description
In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:
Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
Deal structures and the BD side of ADCs, and their extended revenue generation potential
Where the field is headed, in terms of clinical, BD and commercial standpoints
Read and connect with our authors: The Transactional Landscape Of ADCs: A Payday for Payloads
Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
Deal structures and the BD side of ADCs, and their extended revenue generation potential
Where the field is headed, in terms of clinical, BD and commercial standpoints
Read and connect with our authors: The Transactional Landscape Of ADCs: A Payday for Payloads
Released:
Aug 29, 2023
Format:
Podcast episode
Titles in the series (27)
Life Science SPACs: A Forward Look at this Evolving Asset Class: In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory Benning and Vasilios Kofitsas of Back Bay’s investment banking team to talk about the market of Special Purpose Acquisition Companies (SPACs). by Back Bay Life Science Report